BridgeMD
New treatment option for Prolonged Grief Disorder (PGD)
Official title Technology-supported Interventions for Prolonged Grief Disorder (PGD)
ClinicalTrials.gov ID: NCT06932120
What this study is testing
- What it's testing
- The main aim of this project is to test the efficacy of two formats of delivering an internet- based treatment(GROw) for Prolonged Grief Disorder (PGD) in order to enhance treatment adherence: in a blended format (that combines self-applied treatment online with face-to face sessions with a therapist by videoconference: BF-GROw) and self-applied online format supported by Ecological Momentary Assessment (EMAs) and Ecological Momentary Interventions (EMIs) (iGROw), compared with a waiting list (WL) control group in a community sample of patients with the diagnosis of PGD. The general initial hypothesis is that both treatment conditions (blended format and self-applied format supported by EMAs and EMIs) will significantly produce an improvement in grief symptoms, compared to the WL control group.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older. Healthy volunteers may be eligible.
You may be able to join if
- Being at least 18 years old.
- Meeting diagnostic criteria for Prolonged Grieft Disorder based on the International Classification of Diseases 11 edition (ICD-11).
- Sign an informed consent.
- Ability to understand and read Spanish.
- Ability to use a computer.
You likely can't join if
- Presence of high risk of suicide.
- Presence of axis I severe mental disorder: substance abuse or dependence, psychotic disorder, dementia, bipolar disorder; severe personality disorder...
- Receiving other psychological treatment during the study.
- An increase and/or change in the medication during the study period, in the case of receiving pharmacological treatment.
See the full eligibility criteria
- Being at least 18 years old.
- Meeting diagnostic criteria for Prolonged Grieft Disorder based on the International Classification of Diseases 11 edition (ICD-11).
- Sign an informed consent.
- Ability to understand and read Spanish.
- Ability to use a computer.
- Having an e-mail address.
- Having an internet connection and Access to a Smartphone.
- Presence of high risk of suicide.
- Presence of axis I severe mental disorder: substance abuse or dependence, psychotic disorder, dementia, bipolar disorder; severe personality disorder or medical illness whose severity or characteristics prevent...
- Receiving other psychological treatment during the study.
- An increase and/or change in the medication during the study period, in the case of receiving pharmacological treatment.
The study team makes the final eligibility decision.
Where it's taking place
- Castellon, Castellón de La Plana, Spain
- Castellon, Castellón, Spain
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Castellon, Castellón de La Plana, Spain; Castellon, Castellón, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.